Galien Foundation Selects NovoTTF™ Therapy as a Finalist for the 2013 Prix Galien USA Award

The NovoTTF™-100A System, FDA Approved for Treating Recurrent Glioblastoma (GBM) with Low Intensity Electric Fields, Selected as Award Finalist Second Year

Sep 03, 2013, 09:00 ET from Novocure

ST. HELIER, Jersey, Sept. 3, 2013 /PRNewswire/ -- Novocure announced today that the Galien Foundation has selected the NovoTTFTM-100A System as a finalist for the prestigious Prix Galien USA Award in Best Medical Technology. The Prix Galien Awards honor healthcare companies for outstanding efforts to improve the human condition through medical research and pharmacology. The winners are selected by a preeminent scientific committee that includes several Nobel Laureates. 

"The selection of the NovoTTF-100A System as a finalist for the 2013 Prix Galien USA Awards recognizes the tremendous contributions of Yoram Palti, M.D., Ph.D., Novocure's founder and the inventor of Tumor Treating Fields therapy, to the field of oncology," commented William F. Doyle, Novocure's Executive Chairman. "Dr. Palti's insights and leadership enabled the development of an entirely novel treatment modality for solid tumor cancers and we are pleased that the Galien Foundation has chosen to consider this innovative product for its annual award for a second year."

The Galien Foundation will award the 2013 Prix Galien at its annual ceremony on October 22, 2013 in New York City.

About the Galien Foundation and Prix Galien Awards
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.

The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

About The NovoTTF-100A System
The NovoTTF-100A System is a wearable, non-invasive anti-mitotic device designed for continuous use throughout the day by the patient. The device has been shown in in vitro and in vivo studies to slow tumor growth by inhibiting mitosis, the process by which cells divide and replicate.

The portable delivery system creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death.

The NovoTTF-100A System, a NovoTTF Therapy delivery system, has received marketing approval in the United States (U.S.) and is a CE Marked device cleared for sale in the European Union, Switzerland, Australia and Israel.

Approved Indication
The U.S. Food and Drug Administration (FDA) approved the NovoTTF-100A System for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following confirmed disease recurrence. The device is intended to be used as monotherapy as an alternative to standard medical therapy for recurrent GBM after surgical and radiation options have been exhausted.

Patients should only use the NovoTTF-100A System under the supervision of a physician properly trained in use of the device.

Full prescribing information is available at or by calling toll free 1-855-281-9301.

About Novocure™
Novocure Limited is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors. Novocure Inc., Novocure's U .S. subsidiary, has operations in New York, NY and Portsmouth, NH. Novocure's research center is located in Haifa, Israel. For additional information about the company, please visit


Peter Melnyk, Novocure
(212) 767-7534

SOURCE Novocure